<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900827-0002</DOCNO><DOCID>900827-0002.</DOCID><HL>   Baxter International   Plans to Lower Stake   In Genetics Institute</HL><DATE>08/27/90</DATE><SO>WALL STREET JOURNAL (J), PAGE B5</SO><CO>   BAX GENI</CO><IN>TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)DRUG MANUFACTURERS (DRG)</IN><LP>   WASHINGTON -- Baxter International Inc. said in aSecurities and Exchange filing that it intends to sell &quot;allor part of&quot; its 7.3% stake in Genetics Institute Inc.   Baxter, a medical products and services concern based inDeerfield, Ill., currently holds 1,021,374 shares; innational over-the-counter trading Friday, Genetics Institutestock fell $2 to close at $27.25 a share, valuing Baxter'sstake at $29.4 million.</LP><TEXT>   Baxter's filing gave no reason for its decision to sellits holdings in the Cambridge, Mass., pharmaceuticalsconcern. Baxter doesn't have a representative on GeneticsInstitute's board.   Under a licensing agreement with Genetics Institute,Baxter will make and market a genetically engineeredhemophilia drug developed by Genetics Institute. GeneticsInstitute and Baxter applied in May for approval from theFood and Drug Administration to market the drug; a GeneticsInstitute spokeswoman said the companies expect approval in&quot;mid- to late 1991.&quot;   Baxter president Wilbur H. Gantz said in a statement: &quot;Ourdecision to reduce our holdings in Genetics Institute stocksupports our own financial goals,&quot; and that proceeds would beused to reduce Baxter's debt. He added that Baxter has &quot;anexcellent working relationship&quot; with Genetics Institute, andis &quot;especially enthusiastic&quot; about their joint effort todevelop and market the hemophilia drug.   The drug, known as Recombinate, is a geneticallyengineered form of the bloodclotting protein Factor VIII,which is used by hemophiliacs. The drug is thought to holdpromise as one way to prevent the transmission of blooddiseases through the use of Factor VIII derived from plasma.</TEXT></DOC>